Center for Medical Genetics, Department of Metabolism, Chiba Children's Hospital, 579-1 Heta-cho, Midori-ku, Chiba, 266-0007, Japan.
Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan.
Orphanet J Rare Dis. 2020 Jul 24;15(1):169. doi: 10.1186/s13023-020-01441-5.
Hepatocerebral mitochondrial DNA depletion syndrome (MTDPS) is a disease caused by defects in mitochondrial DNA maintenance and leads to liver failure and neurological complications during infancy. Liver transplantation (LT) remains controversial due to poor outcomes associated with extrahepatic symptoms. The purposes of this study were to clarify the current clinical and molecular features of hepatocerebral MTDPS and to evaluate the outcomes of LT in MTDPS patients in Japan.
We retrospectively assessed the clinical and genetic findings, as well as the clinical courses, of 23 hepatocerebral MTDPS patients from a pool of 999 patients who were diagnosed with mitochondrial diseases between 2007 and 2019. Causative genes were identified in 18 of 23 patients: MPV17 (n = 13), DGUOK (n = 3), POLG (n = 1), and MICOS13 (n = 1). Eight MPV17-deficient patients harbored c.451dupC and all three DGUOK-deficient patients harbored c.143-307_170del335. The most common initial manifestation was failure to thrive (n = 13, 56.5%). The most frequent liver symptom was cholestasis (n = 21, 91.3%). LT was performed on 12 patients, including nine MPV17-deficient and two DGUOK-deficient patients. Among the 12 transplanted patients, five, including one with mild intellectual disability, survived; while seven who had remarkable neurological symptoms before LT died. Five of the MPV17-deficient survivors had either c.149G > A or c.293C > T.
MPV17 was the most common genetic cause of hepatocerebral MTDPS. The outcome of LT for MTDPS was not favorable, as previously reported, however, patients harboring MPV17 mutations associated with mild phenotypes such as c.149G > A or c.293C > T, and exhibiting no marked neurologic manifestations before LT, had a better prognosis after LT.
肝脑线粒体 DNA 耗竭综合征(MTDPS)是一种由线粒体 DNA 维持缺陷引起的疾病,导致婴儿期肝功能衰竭和神经并发症。由于与肝外症状相关的不良结局,肝移植(LT)仍然存在争议。本研究的目的是阐明肝脑 MTDPS 的当前临床和分子特征,并评估日本 MTDPS 患者 LT 的结局。
我们回顾性评估了 23 例 MTDPS 患者的临床和遗传发现以及临床过程,这些患者是 2007 年至 2019 年间诊断为线粒体疾病的 999 例患者中的一部分。在 23 例患者中的 18 例中确定了致病基因:MPV17(n = 13),DGUOK(n = 3),POLG(n = 1)和 MICOS13(n = 1)。8 例 MPV17 缺陷患者携带 c.451dupC,所有 3 例 DGUOK 缺陷患者携带 c.143-307_170del335。最初最常见的表现是生长不良(n = 13,56.5%)。最常见的肝脏症状是胆汁淤积(n = 21,91.3%)。12 例患者进行了 LT,包括 9 例 MPV17 缺陷和 2 例 DGUOK 缺陷。在 12 例移植患者中,包括 1 例有轻度智力障碍的患者,有 5 例存活;而在 LT 前有明显神经症状的 7 例患者死亡。5 例 MPV17 缺陷幸存者中,有 c.149G > A 或 c.293C > T。
MPV17 是肝脑 MTDPS 最常见的遗传原因。正如之前报道的那样,LT 治疗 MTDPS 的结果并不理想,但是,患有与轻度表型相关的 MPV17 突变的患者,例如 c.149G > A 或 c.293C > T,并且在 LT 前没有明显的神经表现,在 LT 后具有更好的预后。